Benzamide,N-[7-[[3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-a-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-buten-1-yl)-,sodium salt (1:1) cas no:1476-53-5

NameBenzamide,N-[7-[[3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-a-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-buten-1-yl)-,sodium salt (1:1)
CAS1476-53-5
SynonymsBenzamide,N-[7-[[3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-a-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl)-,monosodium salt (9CI); Novobiocin, monosodium salt (8CI); Novobiocin, sodiumderiv. (6CI,7CI); Albamycin; Albamycin (capsule); Albamycin sodium; Cathomycinsodium; Cathomycin sodium lyovac; Monosodium novobiocin; NSC 2382; Novobiocinmonosodium; Novobiocin sodium; Novobiocin sodium salt; Sodium albamycin; Sodiumnovobiocin; Vulcamycin
EINECS(EC#)216-023-6
Molecular FormulaC31H36 N2 O11 . Na
Molecular Weight634.67

storage temp2-8°C

Hazard Xi: Irritant;
Risk R43
Safety

Poison by intraperitoneal and subcutaneous routes. Moderately toxic by ingestion. Mutation data reported. An antibiotic with serious side effects which include liver and blood disease. It may also promote the development of resistant strains of staphylococcus. When heated to decomposition it emits toxic fumes of NO_x and Na₂O.
Safety Information of Novobiocin, monosodium salt (1476-53-5):
Hazard Codes: Xi,Xn
Risk Statements: 43-36-36/37/38-20/21/22 
20:  Harmful by inhalation 
21:  Harmful in contact with skin 
22:  Harmful if swallowed 
36:  Irritating to the eyes 
37:  Irritating to the respiratory system 
38:  Irritating to the skin 
43:  May cause sensitization by skin contact 
Safety Statements: 36-36/37-26-37/39
26:  In case of contact with eyes, rinse immediately with plenty of water and seek medical advice 
36:  Wear suitable protective clothing 
37:  Wear suitable gloves  
39:  Wear eye/face protection

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
guinea pig	LD50	intraperitoneal	12mg/kg (12mg/kg)		"Compounds Available for Fundamental Research, Volume II-6, Antibiotics, A Program of Upjohn Company Research Laboratory." Vol. 2(6), Pg. -, 1971.
guinea pig	LD50	subcutaneous	28mg/kg (28mg/kg)		"Compounds Available for Fundamental Research, Volume II-6, Antibiotics, A Program of Upjohn Company Research Laboratory." Vol. 2(6), Pg. -, 1971.
mouse	LD50	intraperitoneal	262mg/kg (262mg/kg)		Antibiotics and Chemotherapy Vol. 6, Pg. 226, 1956.
mouse	LD50	intravenous	407mg/kg (407mg/kg)		Antibiotics and Chemotherapy Vol. 6, Pg. 226, 1956.
mouse	LD50	oral	962mg/kg (962mg/kg)		Antibiotics and Chemotherapy Vol. 6, Pg. 226, 1956.
mouse	LD50	subcutaneous	395mg/kg (395mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 386, 1958.
rat	LD50	intravenous	385mg/kg (385mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 386, 1958.
rat	LD50	oral	3500mg/kg (3500mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 386, 1958.
rat	LD50	subcutaneous	450mg/kg (450mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 386, 1958.